Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,791 | -16,019 | -13,124 | -5,566 | -10,008 |
| Depreciation Amortization | 14 | 13 | 13 | 13 | 4 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -936 |
| Other Working Capital | 6,539 | 4,996 | 3,650 | 1,598 | -866 |
| Other Operating Activity | 686 | 582 | 523 | -89 | -4,626 |
| Operating Cash Flow | $-12,552 | $-10,428 | $-8,938 | $-4,044 | $-16,432 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | 382 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $382 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 1,000 | 1,000 | 1,000 | N/A | N/A |
| Common Stock Issued | 11,843 | 8,716 | 3 | 1,729 | 7,020 |
| Other Financing Activity | -1,855 | -882 | 8,274 | -215 | 0 |
| Financing Cash Flow | $10,988 | $8,834 | $9,277 | $1,514 | $7,020 |
| Exchange Rate Effect | -4 | -5 | -7 | -5 | 7 |
| Beginning Cash Position | 3,845 | 3,845 | 3,845 | 3,845 | 13,250 |
| End Cash Position | 2,659 | 2,246 | 4,177 | 1,310 | 3,845 |
| Net Cash Flow | $-1,186 | $-1,599 | $332 | $-2,535 | $-9,405 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,552 | -10,428 | -8,938 | -4,044 | -16,432 |
| Free Cash Flow | -12,552 | -10,428 | -8,938 | -4,044 | -16,432 |